Price
CHART BY
Frequently asked questions
What is Fortress Biotech's market capitalization?
The market capitalization of Fortress Biotech is $74.68M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Fortress Biotech?
Fortress Biotech's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.142. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Fortress Biotech's stock?
Currently, 2 analysts cover Fortress Biotech's stock, with a consensus target price of $10.50. Analyst ratings provide insights into the stock's expected performance.
What is Fortress Biotech's revenue over the trailing twelve months?
Over the trailing twelve months, Fortress Biotech reported a revenue of $59.30M.
What is the EBITDA for Fortress Biotech?
Fortress Biotech's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$101.93M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Fortress Biotech?
Fortress Biotech has a free cash flow of -$80.09M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Fortress Biotech have, and what sector and industry does it belong to?
Fortress Biotech employs approximately 101 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Fortress Biotech's shares?
The free float of Fortress Biotech is 23.02M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $74.68M
- EPS (TTM)
- -$1.142
- Free Float
- 23.02M
- Revenue (TTM)
- $59.30M
- EBITDA (TTM)
- -$101.93M
- Free Cashflow (TTM)
- -$80.09M
Pricing
- 52W span
- $1.325$4.20
Analyst Ratings
The price target is $10.50 and the stock is covered by 2 analysts.
Buy
2
Hold
0
Sell
0
Information
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
- Employees
- 101
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- FBIO
Fundamentals & EOD data from FactSet